<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03850366</url>
  </required_header>
  <id_info>
    <org_study_id>10313</org_study_id>
    <nct_id>NCT03850366</nct_id>
  </id_info>
  <brief_title>HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib</brief_title>
  <official_title>HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib Following Fludarbine/Melphalan/Total Body Irradiation Conditioning Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henry Ford Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Henry Ford Health System</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Now haplo stem cell transplant using bone marrow or peripheral blood is becoming more
      feasible with better regimens to prevent graft versus host disease (GVHD) like post
      transplant cyclophosphamide , tacrolimus, mycophenolate . Recently Bortezomib has also been
      shown to inhibit dendritic cells maturation and function and possesses a number of other
      favorable immunomodulatory effect that can prevent GVHD and help enhance immune
      reconstitution. this study is to assess the engraftment rate in patients with hematologic
      malignancies who need allogeneic stem cell transplant but do not have a suitable matched
      related or unrelated stem cell donor and will get T-cell replete HLA-Haploidentical
      allogeneic peripheral stem cell transplantation using post transplant Cyclophosphamide and
      bortezomib
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 8, 2016</start_date>
  <completion_date type="Anticipated">January 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>engraftment rate</measure>
    <time_frame>within 30 days post transplant</time_frame>
    <description>rate of neutrophil and platelet engraftment post stem cell transplant</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Hematological Malignancy</condition>
  <arm_group>
    <arm_group_label>Bortezomib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>GVHD prophylaxis</description>
    <arm_group_label>Bortezomib</arm_group_label>
    <other_name>cyclophosphamide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-65 years old patient lacking a matched related donor or unrelated donor but have a
             related haploidentical donor (&lt;/= 7/8 allele match at the A, B, C, DR loci with a
             minimum match of 5/10 is required) is identified

          -  Candidate for stem cell transplant in a malignant hematological condition

          -  Karnofsky Performance Scale 0-1

          -  Available donor able to undergo a Peripheral blood stem cells collection

          -  Bilirubin &lt;/= 1.5 mg/dl , aspartate aminotransferase (AST) or alanine aminotransferase
             (ALT) &lt;/= 200 IU/ml for adults.

          -  Serum creatinine clearance &gt;/=60 ml/min (calculated with Cockroft-Gault formula)

          -  Diffusing capacity for carbon monoxide (DLCO) &gt;/= 45% predicted corrected for
             hemoglobin.

          -  Left ventricle ejection fraction &gt; 40%.

          -  Patient or patient's legal representative, parent(s) or guardian should provide
             written informed consent.

        Exclusion Criteria:

          -  Adult who has a suitable related or unrelated donor or cord units available for
             transplant. Suitable donors include 8/8 (HLA-A,B,C and DR, with all loci
             high-resolution typing) or 7/8 related or unrelated donor available within 42 days of
             search initiation

          -  HIV positive; active hepatitis B or C

          -  Patients with active uncontrolled infections.

          -  Liver cirrhosis

          -  Uncontrolled central nervous system involvement by tumor cells

          -  Positive Beta Human chorionic gonadotropin (HCG) test in a woman with child bearing
             potential defined as not post-menopausal for 12 months or no previous surgical
             sterilization.

          -  Inability to comply with medical therapy or follow-up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>shatha farhan</last_name>
    <phone>313 713 3910</phone>
    <email>sfarhan1@hfhs.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Henry Ford hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>shatha farhan</last_name>
      <phone>313-916-5002</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 20, 2019</study_first_submitted>
  <study_first_submitted_qc>February 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2019</study_first_posted>
  <last_update_submitted>February 20, 2019</last_update_submitted>
  <last_update_submitted_qc>February 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Henry Ford Health System</investigator_affiliation>
    <investigator_full_name>Shatha Farhan</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

